Vivek Subbiah/LinkedIn
Jul 5, 2025, 14:39
Vivek Subbiah: It’s Time We Evolve WHO Cancer Classification
Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn:
“Happy 4th everyone!
Delighted to share with the our comment just published in the Lancet Oncology on ‘Bridging Classification and Treatment’
Tumor biology > tumor location. It’s time we evolve WHO cancer classification to match how we treat it: by molecular target, not just anatomy
A hybrid model -organ-based AND genomics-driven- can bridge diagnostics and access, accelerating precision care.”
Title: Bridging tumour classification and treatment
Authors: Vivek Subbiah, Benedikt Westphalen, Guiseppe Curigliano, Fabrice Andre
You can read the Full Article on The Lancet Oncology
More posts featuring Cancer Classification.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 5, 2025, 20:31
Jul 5, 2025, 20:15
Jul 5, 2025, 20:00
Jul 5, 2025, 19:18
Jul 5, 2025, 18:52
Jul 5, 2025, 18:38